{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '10.', 'DATA QUALITY ASSURANCE', 'To ensure accurate, complete, and reliable data, the Sponsor or its representatives will do the', 'following:', 'Provide instructional material to the clinics, as appropriate', 'Sponsor start-up training to instruct the Investigators and trial coordinators. This', 'training will give instruction on the protocol, the completion of the eCRFs, and trial', 'procedures.', 'Make periodic visits to the clinic', 'Be available for consultation and stay in contact with the clinical site staff by mail,', 'telephone, and/or fax', 'Review and evaluate eCRF data and use standard computer edits to detect errors in', 'data collection', 'Conduct a quality review of the database', 'In addition, the Sponsor or its representatives will periodically check subject data recorded', 'against source documents at the clinic. The trial may be audited by the Sponsor or its', 'representatives, and/or regulatory agencies at any time. Investigators will be given notice before', 'an audit occurs.', 'To ensure the safety of participants in the trial, and to ensure accurate, complete, and reliable', 'data, the Investigator will keep records of laboratory tests, clinical notes, and subject medical', 'records in the subject files as original source documents for the trial. If requested, the', 'Investigator will provide the Sponsor, applicable regulatory agencies, and applicable ECs with', 'direct access to original source documents.', '10.1.', 'Data Capture System', 'An electronic data capture system (eDC) will be used in this trial. The clinical site will maintain', 'a separate source for the data entered by the clinical site into the Sponsor-provided electronic', 'data capture system.', 'Case report form data will be encoded and stored in a clinical trial database. Data managed by', 'a', 'central vendor, such as laboratory test data or ECG data, or any data for which electronic', \"documentation is provided by the subject, will be stored electronically in the central vendor's\", 'database system.', 'Any data for which paper documentation provided by the subject will serve as a source', \"document will be identified and documented by each clinical site in that center's trial file. Paper\", 'documentation provided by the subject may include, for example, a paper diary to collect subject', 'reported outcome measures (e.g., a rating scale), a daily dosing schedule, or an event diary.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '71']['SPIMM-301 Version 4.0', '15 June 2018', '11.', 'SAMPLE SIZE AND STATISTICAL METHODS', '11.1.', 'Determination of Sample Size', 'The sample size of 202 subjects provides 90% power to detect a 30-meter difference between', 'treatment groups in the 6MWT and also 90% power to detect a one unit difference in the', 'PMMSA Total Fatigue Score, assuming standard deviations of 60 meters for 6MWT and 2 units', 'for the PMMSA Total Fatigue Score, at an alpha-level of 0.025. The two-sided alpha-level of', '0.025 is to account for a possible multiplicity adjustment as given in Section 11.2.5.5.', '11.2.', 'Statistical and Analytical Plans', '11.2.1.', 'General Considerations', 'Data will be tabulated (by treatment group) using descriptive statistics (number of subjects,', 'mean, median, standard deviation, minima, and maxima) for continuous variables and using', 'frequencies and percentages for discrete variables. Inferential statistics will be presented where', 'specified. A comprehensive statistical analysis plan (SAP) will be written and approved prior to', 'database lock. This SAP will detail how missing values are to be handled, windows for trial', 'visits, and how other analysis considerations will be addressed.', 'Statistical tests (where performed) will be 2-sided at the alpha=0.05 level of significance, except', 'where otherwise noted to adjust for multiplicity.', '11.2.2.', 'Analysis Populations', 'Statistical analysis will be performed using the following populations:', 'Safety Population - Includes all trial subjects who receive at least 1 dose of IMP.', 'Subjects will be analyzed according to the actual treatment they receive.', 'Intent-to-Treat (ITT) Population - Includes all trial subjects who receive at least one', 'dose of IMP. Subjects will be analyzed according to the treatment group they were', 'randomized to and generally included in efficacy analyses for which post-baseline', 'data are available.', 'Per-Protocol (PP) Population - Includes all ITT subjects without major protocol', 'violations/deviations. The list of major protocol violations/deviations will be', 'identified and specified in the SAP prior to final database lock for the trial that would', 'lead to exclusion for the PP analysis.', 'Pharmacokinetic (PK) Population - Includes all trial subjects who have at least one', 'PK sample taken during their participation.', '11.2.3.', 'Subject Disposition', 'Subject disposition (including the number and percent of subjects who are randomized, who', 'receive randomized treatment, who are included in each analysis population, who prematurely', 'discontinue and reasons for discontinuation, and who complete the trial) will be tabulated by', 'treatment group. The number and percentage of subjects by exposure duration will be tabulated.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '72']\n\n###\n\n", "completion": "END"}